Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Debt to Equity (2018 - 2023)

Protagonist Therapeutics' Debt to Equity history spans 6 years, with the latest figure at $0.0 for Q2 2023.

  • For Q2 2023, Debt to Equity fell 88.61% year-over-year to $0.0; the TTM value through Jun 2023 reached $0.0, down 88.61%, while the annual FY2022 figure was $0.0, 89.32% down from the prior year.
  • Debt to Equity for Q2 2023 was $0.0 at Protagonist Therapeutics, down from $0.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.03 in Q2 2021 and bottomed at $0.0 in Q2 2023.
  • The 5-year median for Debt to Equity is $0.01 (2019), against an average of $0.01.
  • The largest annual shift saw Debt to Equity surged 432.37% in 2021 before it plummeted 99.06% in 2022.
  • A 5-year view of Debt to Equity shows it stood at $0.02 in 2019, then plummeted by 38.09% to $0.01 in 2020, then crashed by 69.33% to $0.0 in 2021, then crashed by 89.32% to $0.0 in 2022, then plummeted by 89.37% to $0.0 in 2023.
  • Per Business Quant, the three most recent readings for PTGX's Debt to Equity are $0.0 (Q2 2023), $0.0 (Q1 2023), and $0.0 (Q4 2022).